Strategic Evolution and Operational Context

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

• Management is transitioning from a historical model of one IPO every 18 months to a target of 3 to 5 launches annually by leveraging AI to remove information inertia.

• The firm identifies AI as a 'game changer' that compresses deep due diligence and S-1 preparation timelines from months to weeks through agentic models and expert-led SOPs.

• MDB has invested approximately $4 million annually since its IPO to stand up MDB Direct and PatentVest as independent, high-value enterprises ready for monetization.

• Performance attribution for the past year reflects a 'tough road' where internal expectations were not met, leading to cost-cutting measures including retracted RSUs and frozen raises.

• The strategic rationale for going public was to transform public venture into a scalable asset class, building diversified portfolios rather than single-company investments for retail clients.

• Management attributes the stock's decline to a difficult microcap environment characterized by horrific dilution and a slower-than-anticipated ramp-up of the new operating model.

Outlook and Strategic Initiatives

• MDB plans to spin out and finance PatentVest as an independent entity before the end of 2025, with a target for a public listing in 2027.

• The company is seeking strategic partnerships for MDB Direct to monetize the self-clearing asset and solve the 'distribution gap' required for higher-volume IPO scaling.

• Post-spin-out, management expects annual operating expenses to drop to approximately $6 million, creating significant financial leverage for future equity earnings.

• The Paulex IPO is targeted for September 2025, timed to coincide with the initiation of clinical trials for its diabetes treatment.

• Future scaling is contingent on broadening distribution beyond the current 675 active accounts to avoid over-reliance on a few large investors.

Asset Specifics and Risk Factors

• MDB Direct is positioned as a rare self-clearing asset in the microcap space, which management believes holds significant value for firms lacking internal clearing capabilities.

• PatentVest has transitioned into an Alternative Business Structure (ABS) law firm to provide attorney-client privilege, a move intended to disrupt the $10 billion to $15 billion U.S. patent prosecution market.

• Management explicitly flags 'distribution gap' as their primary concern, noting that the ability to find investors is currently a tighter bottleneck than finding high-quality companies.

• The portfolio includes a 'serendipitous' investment in Buda Juice, justified by a global consumer shift toward fresh, non-processed foods and the company's existing profitability.